Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-07-11
2006-07-11
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S426000, C424S428000, C514S772300, C514S012200, C523S115000
Reexamination Certificate
active
07074412
ABSTRACT:
The present invention relates to pharmaceutical compositions containing a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier, such as a biodegradable polymer. The present invention further relates to methods of treating orthopaedic and dental, including periodontal, diseases by simultaneously administering a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier to patients in need of such treatment.
REFERENCES:
patent: 5324519 (1994-06-01), Dunn et al.
patent: 2003/0022828 (2003-01-01), Akella et al.
patent: 2003/0104029 (2003-06-01), Pirhonen et al.
patent: 2003/0105530 (2003-06-01), Pirhonen et al.
patent: 0 433 225 (1991-06-01), None
patent: 0 560 014 (1993-09-01), None
patent: 1 126 822 (2001-08-01), None
patent: WO 03/060076 (2003-07-01), None
Andriano, K., et al. J. Biomed. Mat. Res. (Appl. Biomater.) 2000, vol. 53, pp. 36-43.
Li, R., and J. Wozney. Trends in Biotech. 2001, vol. 19(7), pp. 255-265.
Daluiski et al., Nature Genetics, 2001, vol. 27, pp. 84-88.
Wolfam et al., J. Clin Invest. 1997, vol. 100, pp. 321-330.
Bodine et al., “Development and Characterization of a Conditionally Transformed Adult Human Osteoblastic Cell Line,”J. Bone Mineral Res., 11:806-819 (1996).
Dahlin et al., “Membrane-Induced Bone Augmentation at Titanium Implants,”Int. J. Periodontics Rest. Dent., 11(4):273-281 (1991).
Hämmerle and Karring, “Guided bone regeneration at oral implant sites,”Peridontol. 2000, 17:151-175 (1998).
Israel et al., “Expression and Characterization of Bone Morphogenetic Protein-2 in Chinese Hamster Ovary Cells,”Growth Factors, 7:139-150 (1992).
Johnson et al., “Distal Metaphyseal Tibial Nonunion,”Clin. Orthop., 250:234-240 (1990).
Katagiri et al., “The Non-Osteogenic Mouse Pluripotent Cell Line, C3H10T1/2, Is Induced to Differentiate into Osteoblastic Cells by Recombinant Human Bone Morphogenetic Protein-2,”Biochem. Biophys. Res. Com., 172:295-300 (1990).
Klinge et al., “Osseous Response to Implanted Natural Bone Mineral and Synthetic Hydroxylapatite Ceramic in the Repair of Experimental Skull Bone Defects,”J. Oral Maxillofac. Surg, 50:241-249 (1992).
Lowry et al., “The Quantitative Histochemistry of Brain,”J. Biol. Chem., 207:19-37 (1954).
Nyman and Lang, “Guided tissue regeneration and dental implants,”Periodontol. 2000, 4:109-118 (1994).
Reddi, “Bone Morphogenetic Proteins: an Unconventional Approach to Isolation of First Mammalian Morphogens,”Cytokine&Growth Factor Review, 8:11-20 (1997).
Rose and Oreffo, “Bone Tissue Engineering: Hope vs Hype,”R.O.C. Biochem. Biophys. Res. Com., 292:1-7 (2002).
Ruppert et al., “Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity,”Eur. J. Biochem.,237:295-302 (1996).
Suzawa et al., “Extracellular Matrix-Associated Bone Morphogenic Proteins Are Essential for Differentiation of Murine Osteoblastic Cellsin Vitro,” Endocrin, 140(5):2125-2133 (1999).
Weber et al., “Disulfide Bridge Conformers of Mature BMP Are Inhibitors for Heterotopic Ossification,”Biochem. Biophys. Res. Commun., 286:554-558 (2001).
Weber et al., “Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres,”Int. J. Oral Maxilofac. Surg., 31:60-65 (2002).
Wozney and Rosen, “Bone Morphogenetic Protein and Bone Morphogenetic Protein Gene Family in Bone Formation and Repair,”Clin. Orthop. Rel. Res, 346:26-37 (1998).
Wozney et al., “Novel Regulators of Bone Formation: . . . ,”Science, 242:1528-1534 (1988).
The Biomedical Engineering Handbook, Ed. J.D. Bronzino, CRC Press, Boca Raton, FL, Chapter 41, pp. 1-22 (2000).
Bartsch et al., “Acute Toxicity of Various Solvents in the Mouse and Rat,”Drug Res., 26(8):1581-1583 (1976).
Wozney “Bone Morphogenetic Proteins,”Progress in Growth Factor Research, 1:267-280 (1989).
Banner & Witcoff , Ltd.
Garnett Daniel C.
Romeo David S.
The University of Zurich
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547674